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Haemophilus influenzae (Hi) is a major pathogen associated with community-acquired respiratory tract infections (RTIs). Even though antibiotic therapy is of great
meaning in Hi infections, its efficacy may be compromised by the emergence of resistant strains to β-lactams since this antibiotic class is the most used for Hi and RTIs.
The two well known mechanisms of β-lactam antibiotics resistance in Hi are: β-lactamase production, which is responsible for the enzymatic inactivation of the
antibiotic, and a non-enzymatic mechanism, that involves decreased affinity for β-lactams due to altered penicillin-binding proteins (PBPs)1,2.
The aim of this study is to characterize ampicillin resistance mechanisms in clinical strains of Hi collected in our laboratory between 2009 and 2012.
1. Introdution
Haemophilus influenzae strains
 Two hundred and thirty five isolates were chosen according to their
ampicillin MICs: 140 BLNAR (MIC≥1mg/L), 32 susceptible strains
(BLNAS; MIC<1mg/L) and 63 β-lactamase producers (BLPAR) to be
analyzed.
2. Material and Methods
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3. Results
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No. of 
isolates b
Amino acid substitution
Group 
a
near SSN motif near KTG motif
Bla - Bla + Asp350 Ser357 Ala368 Met377 Ser385 Ala437 Ile449 Leu456 Gly490 Ala502 Arg517 Asn526 Ala530 Thr532 Val547 Ala554 Asn569
I 1 Val Thr Ser
1 His Val Thr Ser
1 Ser His
II a 1 Asn Glu Lys Ser
1 Glu Lys Ser Val Ser
1 Glu Lys Ser
2 1 Lys
1 Asn Ile Lys Val Ser
1 Asn Lys Val
II b 16 1 Asn Ile Glu Val Lys Val Ser
2 1 Asn Ile Val Lys
1 Asn Ile Val Lys Val
3 Ile Glu Val Lys Val Ser
1 Ile Val
1 Ile Val Lys Val Ser
17 9 Asn Ile Val Lys Val Ser
3 Glu Val Lys Val Ser
5 1 Val Lys Val Ser
4 1 Val Lys
Methods
 Antibiotic susceptibility was determined by the broth micro dilution
method, according to the CLSI guidelines3;
 Beta-lactamase production was determined by a nitrocefin assay;
 Characterization of TEM-1/ROB-1 was performed by PCR Multiplex4;
 Amplification of bexA gene and capsular serotype characterization
were also performed by PCR5;
 Amplification and sequencing of ftsI gene was performed as
previously described6
 Among gBLNAR and gBLPACR strains
there were 40 different mutation patterns, that
were included in the six previously described
groups and subgroups (I, IIa, IIb, IIc, IId, III-like)
(Table 1).
 The most common amino acid
substitutions were located near KTG motif:
V547I (174/199, 87.4%), N526K (153/199, 76.9%)
4. Discussion and 
Conclusion
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Figures III and IV: Phenotypes of H. influenzae clinical isolates collected
between 2009 and 2012, and correspondent genotype (after sequencing).
Figures I and II: Distribution of H. influenzae clinical isolates studied by
Gender and Age Groups.
a The strains with mutations in the ftsI gene were classified into six groups: I and II (a, b, c and d) according to Dabernat et al. (8)  
and III-like according to García-Cobos et al. (9);
b Bla+, β-lactamase-producing strains; Bla-: β-lactamase-non-producing strains;
1 Val
4 2 Asn Val Lys Val Ser
2 Asn Ile Ser Val Lys Val Ser
1 Asn Ser Val Lys Val Ser
4 Asn Ile Val Val Lys Val Ser
3 1 Asn Ile Cys Val Lys Val Ser
1 Asn Pro Ile Val Lys Val Ser
II c 31 Asn Thr Lys Val Ser
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2 2 Thr Lys Val
4 Thr Lys
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II d 6 3 Val Lys Val Ser
1 Ile Val Lys Val Ser
1 Val Lys
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III-like 5 Asn Ser Ile Thr His Lys Ser Val
1 Asn Ser Ile Thr His Lys Ser Val Ser
Misc 17 18
and N569S (143/199, 71.9%) (Table 1).
 Strains with ftsI mutations were less
susceptible to the β-lactam antibiotics studied
(data not shown).
 Comparing these results with previously
ones, performed in our laboratory (between
2001 and 2008)2 we are assisting to an increase
of susceptible strains (ampicillin MIC<2mg/L)
as well as resistant strains (β-lactamase
producers) with mutations in the ftsI gene,
being so called gBLNAR and gBLPACR.
 CLSI breakpoints alone can’t characterize
these strains as susceptible or resistant in the
susceptibility tests performed routinely in the
laboratory7. In this way, a continuous research
on breakpoints and methodologies to better
define strains of this kind is of crucial
importance.
 In conclusion, we emphasize the
importance of continuing surveillance studies
of this nature as essential tools to define
trends in the antibiotic resistance of Hi.
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Table 1: Amino acid substitutions identified in the transpeptidase domain of the ftsI gene.
